Trellus Health Share Discussion Threads

[senttothegallows] 01/7/2022 10:27

Having watched the recent presentation and the fact they forecast profitability q4 next year and won't need to come back to the market.
Currently valued at less than cash the ip and infrastructure is worth a significant amount. Too cheap imho

[riddlerone] 29/6/2022 11:54

By the time this dividend lands in my account I doubt it will even buy me a bowl of soup.

[wan] 29/6/2022 06:59

Digital Health Center of Excellence Updates from CDRH
U.S. Food and Drug Administration sent this bulletin at 06/27/2022

June 27, 2022

Digital health is driving a revolution in health care, and the U.S. Food and Drug Administration's (FDA) Center for Devices and Radiological Health (CDRH) is helping set the stage for these advances. As an important step in promoting the advancement of digital health technology, CDRH established the Digital Health Center of Excellence (DHCoE). This update highlights DHCoE activities that promote awareness and consistent application of digital health regulatory policies to foster equity in health care; pioneer the development and enhancement of digital health regulatory paradigms; and cultivate digital health-focused collaborations.

Discover how CDRH’s Digital Health Center of Excellence is helping set the stage for the advancement of digital health technologies to help protect and promote public health.

[wan] 25/6/2022 07:40

First a quick summary/reminder -

Trellus Health is a leading pioneer in validated resilience-driven care and the first digital health company focused on the intersection of chronic physical conditions and mental health.

Trellus Health's digital-first chronic care management solution integrates convenient access to a licensed multidisciplinary care team with a suite of tools for resilience assessment, education and behavior modification, remote monitoring, health maintenance and prevention. Through its TrellusElevate™ connected care platform and companion App, the Company enables coordination and delivery of expert whole-person care, addressing both clinical and behavioral health together, in context, to improve outcomes and reduce healthcare costs for patients, employers, and the healthcare system.

Thus, I found the following very interesting and encouraging -

Telehealth visits for mental health continue to rise despite dropping in every other specialty
Mental health is bucking the overall trend in telehealth utilization. A new report found that telehealth accounted for 87% of mental health appointments booked last month. That percentage is continuing to climb, despite virtual care visits declining across all other specialties.
By KATIE ADAMS

Jun 23, 2022

The explosive use of virtual care that occurred during the early months of the pandemic has dropped drastically across all specialties but one — mental health. In fact, telehealth utilization among mental health patients is continuing to climb, according to a new report.

By contrast, when telehealth use for mental health appointments was examined, the numbers tell a different story. In May 2020, 74% of mental health appointments booked on Zocdoc were virtual. It rose to 85% in May 2021 and 87% in May 2022.

Virtual mental health visits will continue to grow, said Richard Fine, Zocdoc’s chief commercial officer. He said that while every other specialty has shifted back to in-person care, mental health is pivoting even more toward telehealth.

“The conversational nature of mental health appointments — and the discretion, ease and efficiency of talking to a therapist from home without a commute — means that telehealth is likely to remain patients’ first choice for mental health care,” he said.


The Report referred to -

[adobbing] 24/6/2022 19:58

@sharw My TRLS in specie shares have now appeared in my ISA account.
I’m now the proud owner of 92 shares worth a grand total of £15.64 😂

[wan] 23/6/2022 06:50

Although I had cooled on my personal investment rationale for Trellus Health (I still hold), mainly due the vast amount of competition from the raft of digital health companies, where inevitably there is some overlap with regard to addressing chronic conditions.

Todays news of a recent hire reminded me that Trellus is commercialising a scientifically validated, resilience-based, connected health solution for chronic condition management. And that the Trellus approach is based on a scientifically validated method developed at the Mount Sinai Health System.

With the above in mind, the following provides food for thought in terms of Trellus perhaps having an important edge in the digital health sector wallowing in cash, but with not many of those companies being 'differentiated' or indeed scientifically validated -

Lack of clinical evidence ‘major gap’ in digital health: study
Published June 22, 2022

Dive Brief:
Most digital health companies have a low level of “clinical robustness” as measured by their number of regulatory filings and clinical trials, according to a paper published in the Journal of Medical Internet Research.

Researchers at Rock Health and Johns Hopkins University analyzed the activity of 224 companies that have collectively raised $8.2 billion since 2011 to determine their clinical rigor. The median score on the robustness scale was one, reflecting the fact that almost half of the companies had no regulatory filings or clinical trials to their names.

The researchers framed the low clinical robustness scores as evidence of “a major gap in health care technology,” adding that there is a “significant opportunity” for companies that differentiate themselves through a more rigorous approach.
Full article -

The Rock Health Report -

Back in February, Trellus also launched a Program to accelerate patient recruitment and real-world evidence for whole-person resilience driven care management for people living with Inflammatory Bowel Disease (IBD) -

As previously stated in the Company’s trading update from December 2021, the focus for 2022 will be on recruitment of DTC patients and the establishment of additional demonstration programs and B2B contracts. This will enable Trellus to gather real world evidence to validate and reinforce the health quality and economic outcomes shown in the co-founders’ published research, as well as informing further product development.

Recently published clinical research demonstrated that IBD patients show significant improvements in resilience and reductions in expensive unplanned healthcare usage by utilising the GRITTTM methodology and multidisciplinary care model that was exclusively licensed from the Icahn School of Medicine at Mount Sinai. As greater evidence is amassed in 2022, the Company expects to enter regional and national multi-year contracts with US employers and health insurance payers from 2023 onwards.

[adobbing] 22/6/2022 05:55

Got the same email a while after you posted, good to see something finally happening!

[sharw] 21/6/2022 16:15

AT LAST! No reply from Walbrook but my ii a/c now says:


Stock
TRELLUS HEALTH A ORDINARY
Event Type
Mandatory Conversion

Please be aware that the restrictions on the Trellus Health A shares issued as in-specie distribution from EKF Diagnostics in December 2020 have now been lifted.

We have now received the new unrestricted Ordinary share certificates in Trellus Health plc and are currently depositing these into electronic format. Once this is complete your account will be updated with the new shares and you will be able to trade the shares through our website as normal.

I am wondering whether EKF failed to make clear at the time what they said yesterday regarding Verici Dx that it is not instant on expiry:

Within 28 days of the expiry of the Lock-up Period, Relevant EKF Shareholders will be sent a certificate for the number of Investment Verici Shares indicated above, which shareholders will then have the option to dematerialise and hold via CREST.

[adobbing] 10/6/2022 14:21

Thanks sharw
Let me know if you hear anything, I’m not desperate for the cash, which is probably not much anyway.
It would be good to resolve, though!

[sharw] 10/6/2022 13:20

adobbing - just checked my ii a/c and still not there, today being the 8th working day since they should have been released. Googled Broadway Nominees to see if I could contact them and all I could get was Companies House who have them as a dormant company!!

I have emailed Walbrook who do Investor Relations for both EKF and TRLS.

[e-mail]

[adobbing] 01/6/2022 08:03

Just checked their website and found this -

“Restrictions in transfer of AIM Securities

There are no restrictions on the transfer of the Company’s ordinary shares except for shareholders who received distribution in specie from EKF Diagnostic Holdings plc which will expire on 28 May 2022.”

Do you think this now requires action at the company end or the ISA provider end?

I’d like to give somebody the nudge required, but unsure who!

[9degrees] 31/5/2022 11:31

same as barclays smart investor

[adobbing] 31/5/2022 07:15

My “in specie” shares still showing in my ii ISA with £0 value.

[adobbing] 27/5/2022 09:30

I will check my in specie shares on Monday, still currently showing in my ii ISA with £0 value.
At least they back pedalled on their demand that I had to love them out of the ISA, probably because they didn’t know how to do it!

[wan] 27/5/2022 09:21

Yes that's correct.

[9degrees] 27/5/2022 08:50

28 may is unlock day isn't it for in specie dividend shares ? Tomorrow
ie 365 days after admission to Aim

[brummy_git] 10/5/2022 09:03

Analyst comments wrt today's prelims.

www.linkedin.com/posts/paul-hill-a5994116_trls-trls-activity-6929715419037483009-tkEi?utm_source=linkedin_share&utm_medium=member_desktop_web

[wan] 10/5/2022 07:53

Interesting evolution/change in strategy, which should be a more scalable, robust and sustainable offering, with managements expectation to deliver a significant number of additional patients in Q4 2022.

From my perspective, whilst the evolution in strategy is welcome (and needed), it will be interesting to see how differentiated the Trellus offering is, of which the delivery of a significant number of patients across B2B and DCT, including those resulting from the advanced discussions with numerous large pharmaceutical companies and patient advocacy groups, will likely prove to be an important indicator for what lies ahead, especially as this will be for only IBD.

Furthermore, expanding into other chronic conditions that can benefit from a 'disease-agnostic' approach to assessing and building resilience and thereby improving mental health, if proven 'commercially' to demonstrate meaningful improvements in patient outcomes whilst generating significant cost savings for healthcare payers, along with the significant unmet need, could result in very high rates of growth.

Therefore, against a challenging backdrop, the next 6 months could be pivotal (one way or another).

[adobbing] 31/3/2022 12:47

Yes, I will probably look for an alternative to ii, they aren’t easy to deal with!
Although I’m struggling to see a better alternative!

[sharw] 31/3/2022 12:02

adobbing - thanks for the update. What a shambles! They are still referring to the 'A' ordinary shares that I pointed out to them 4 weeks ago have not existed since 28th May last year.

[sharw] 11/3/2022 18:17

adobbing - I have now had a reply saying that the line in my portfolio for Trellus is a dummy line to reflect those shares which I am due to receive in the future. This makes their statement to you all the more bizarre - if it is a dummy line there is nothing to be moved elsewhere!

[adobbing] 04/3/2022 20:57

@sharw

Thanks for the update.
I’d almost forgotten about them, until I got the note.
My understanding was that they would convert at some point in time, to tradable shares.
I did buy some Trellus and my original intention was to hold until the two holdings merged, then sell.
But with the fall in price I liquidated those a while back.

I’ll follow up with them next week!

[sharw] 04/3/2022 20:30

adobbing - just seen your note re ii action needed. I find this quite extraordinary - these were issued over a year ago - why has ii only just taken action - I had a share which delisted and my memory says the rule then was that you had 30 days to transfer out of an ISA. Furthermore there have been no other comments here on other brokers doing the same.

I think you should challenge this on the grounds that they are talking about Trellus Health A ordinary shares and these no longer exist, Check this -

As I read it the A ordinary shares converted to ordinary shares on 28th May last year (on AIM admission) and those shares certainly are ISA admissable unless there is some HMRC clause that says not because you are prevented from trading them until 28th May this year.

I have now told ii about this wrong description (they are in my trading a/c so I did not get the message you did) saying that if they are correctly described it will show the market value, not zero.

[brummy_git] 04/3/2022 15:47

Justin Waite & I of Vox Markets discussed Trellus health here today (starts 47:30).

www.voxmarkets.co.uk/articles/stocks-to-follow-on-vox-markets-4th-march-2022-ef5d2a0